Hexarelin
Synthetic hexapeptide growth-hormone secretagogue
Also known as Examorelin, EP-23905
A GHRP-6 analogue with a 2-methyl-tryptophan substitution, studied for GH release and, separately, for cardiac effects attributed to CD36 binding.
Technical information
Values are shown with their status. “Verified” means the value has been checked against a primary database such as PubChem.
- Classification
- Synthetic hexapeptide growth-hormone secretagogue
- CAS number
- 140703-51-1 Pending
- Molecular formula
- C47H58N12O6 Pending
- Molecular weight
- 887.0 g/mol Pending
- Sequence / structure
- His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 Pending
Some values are still being checked and should be treated as provisional until marked verified.
How this compound is tested
LC-MS identity (mass reflecting the 2-methyl-Trp residue) and HPLC purity.
Research background
Hexarelin differs from GHRP-6 by a single methylated tryptophan, which increases stability and potency. It has been studied in GH-release physiology and in cardiovascular research, where binding to the scavenger receptor CD36 has been proposed as a GH-independent mechanism.
Mechanisms investigated in published research
These are the mechanisms examined in the cited literature. Describing them is not a claim that the compound produces any effect in humans.
- GHS-R1a agonism.
- CD36 binding in cardiac tissue, investigated in rodent ischaemia models.
Summary of evidence
Laboratory and animal findings are kept separate from human clinical evidence.
Preclinical findings
Rodent studies have reported cardioprotective endpoints in ischaemia–reperfusion models; GH-release pharmacology is well characterised in animals.
Human clinical evidence
Clinical pharmacology studies in the 1990s examined GH release in healthy volunteers and in several patient groups; no medicinal product was approved.
Limitations and open questions
- Desensitisation of GH response with repeated administration reported in early studies.
- Cardiac findings are preclinical.
- Prohibited in sport under the WADA list.
Scientific references
Publications cited on this page. Links open the publisher or PubMed record.
No references have been published for this entry yet.
Research use only
Hexarelin is described here for laboratory research. It is not approved for human or veterinary use unless a regulator has said otherwise, and nothing on this page is medical advice or guidance on administration. A disclaimer does not by itself make any activity lawful. Full disclaimer.
Contact options
Talk to the Positive Peptides team about Hexarelin
Order enquiries, documentation requests and technical questions about this compound — we answer directly, usually within two working days.
Related compounds
Growth Hormone Axis Research99% purityGHRP-2
Synthetic hexapeptide growth-hormone secretagogue
A second-generation GHRP with higher potency than GHRP-6. Approved in Japan as a diagnostic agent (pralmorelin) for growth-hormone deficiency.
Growth Hormone Axis Research99% purityGHRP-6
Synthetic hexapeptide growth-hormone secretagogue
One of the first synthetic growth-hormone-releasing peptides, developed from met-enkephalin analogues. Its discovery led to the identification of the ghrelin receptor.
Growth Hormone Axis Research99% purityIpamorelin
Pentapeptide growth-hormone secretagogue (ghrelin receptor agonist)
A synthetic pentapeptide agonist of the growth-hormone secretagogue receptor (GHS-R1a). Described in its original publication as selective for GH release with little effect on ACTH or cortisol.